Journal of Biological Chemistry
Volume 277, Issue 38, 20 September 2002, Pages 35402-35410
Journal home page for Journal of Biological Chemistry

MECHANISMS OF SIGNAL TRANSDUCTION
β12-Adrenergic Receptor Heterodimerization Regulates β2-Adrenergic Receptor Internalization and ERK Signaling Efficacy*

https://doi.org/10.1074/jbc.M204163200Get rights and content
Under a Creative Commons license
open access

β1- and β2-adrenergic receptors (β1AR and β2AR) are co-expressed in numerous tissues where they play a central role in the responses of various organs to sympathetic stimulation. Although the two receptor subtypes share some signaling pathways, each has been shown to have specific signaling and regulatory properties. Given the recent recognition that many G protein-coupled receptors can form homo- and heterodimers, the present study was undertaken to determine whether the β1AR and β2AR can form dimers in cells and, if so, to investigate the potential functional consequences of such heterodimerization. Using co-immunoprecipitation and bioluminescence resonance energy transfer, we show that β1AR and β2AR can form heterodimers in HEK 293 cells co-expressing the two receptors. Functionally, β-adrenergic stimulated adenylyl cyclase activity was found to be identical in cells expressing β1AR, β2AR, or both receptors at similar levels, indicating that heterodimerization did not affect this signaling pathway. When considering ERK1/2 MAPK activity, a significant agonist-promoted activation was detected in β2AR- but not β1AR-expressing cells. Similarly to what was observed in cells expressing the β1AR alone, no β-adrenergic stimulated ERK1/2 phosphorylation was observed in cells co-expressing the two receptors. A similar inhibition of agonist-promoted internalization of the β2AR was observed upon co-expression of the β1AR, which by itself internalized to a lesser extent. Taken together, our data suggest that heterodimerization between β1AR and β2AR inhibits the agonist-promoted internalization of the β2AR and its ability to activate the ERK1/2 MAPK signaling pathway.

Cited by (0)

*

This work was supported in part by grants from the Heart and Stroke Foundation of Québec and the Canadian Institutes for Health Research (to T. E. H. and M. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by a scholarship from the Institut de Cardiologie de Montréal.

These authors contributed equally to this work.

**

Supported by a scholarship from the Fonds de Formation Chercheurs et Aide Recherche/Fonds de la Recherche en Santé du Québec (FCAR-FRSQ).

§§

Holder of a Canada Research Chair in Molecular and Cellular Pharmacology.